AstraZeneca is expected to enter its oral weight-loss candidate elecoglipron into phase 3 trials later this year.
发布者:BY MARKETWIRE,转转请注明出处:https://robotalks.cn/astrazeneca-takes-important-step-towards-market-with-weight-loss-tablet/
AstraZeneca is expected to enter its oral weight-loss candidate elecoglipron into phase 3 trials later this year.
发布者:BY MARKETWIRE,转转请注明出处:https://robotalks.cn/astrazeneca-takes-important-step-towards-market-with-weight-loss-tablet/